Liability for Opioid Epidemic – July 18, 2024
July 3, 2024
As outlined below, the Plaintiff issued a Second Fresh as Amended Statement of Claim that named six additional proposed representative plaintiffs in this action, in accordance with Justice Perell’s decision on phase one of the certification motion. However, no potential representative plaintiff with claims against Hikma Labs Inc., Hikma Pharmaceuticals PLC, and West-Ward Columbus Inc. (the “Hikma Defendants“) was identified. The Opioids Action cannot continue against the Hikma Defendants without a representative plaintiff. On July 3, 2024, Justice Perell granted leave to discontinue this action only as against the Hikma Defendants.
